Who is Novavax?
We are a late-stage biotechnology company that promotes improved global health through the discovery, development, and commercialization of innovative vaccines to prevent serious infectious diseases.
We have more than a decade of experience contending with some of the world’s most devastating diseases, including COVID-19, seasonal influenza, RSV, Ebola, MERS, and SARS. Hard-won lessons and significant advances illustrate that our proven technology has tremendous potential to make a substantial contribution to public health worldwide.
Our vaccine candidates are genetically engineered using three-dimensional nanostructures of recombinant proteins critical to disease pathogenesis.
We are also developing proprietary immune-stimulating saponin-based adjuvants at Novavax AB, our wholly owned Swedish subsidiary. Matrix-M™ has been shown to enhance immune responses and has been well tolerated in multiple clinical trials.
Our team is composed of experts in drug development who understand science, technology, medicine, and their global context. Our deeply experienced team is unified in the quest to reduce the burden of infectious disease around the globe.
Meet the leaders who work relentlessly to address urgent
global health needs.
Chief Executive Officer
Research and Development
Chief Medical Officer